舒利迭联合噻托溴铵治疗重度-极重度COPD  

Salmeterol/fluticasone Propionate Combined Tiotropium Bromide for the Treatment of Severe-to-very severe Chronic Obstructive Pulmonary Disease

作　　者：刘玉全[1] 王梅芳[1] 杜春玲[1] 熊畅[1] 李红波[1] 涂明利[1] 

机构地区：[1]郧阳医学院附属太和医院呼吸内科,湖北十堰442000

出　　处：《郧阳医学院学报》2009年第6期585-587,共3页Journal of Yunyang Medical College

摘　　要：目的:观察舒利迭联合噻托溴铵治疗重度-极重度COPD的临床疗效。方法:采用随机、双盲、平行对照试验,47例重度-极重度COPD患者分别给予舒利迭(250μg/50μg)早晚各一次吸入联合噻托溴铵胶囊(18μg)或安慰剂每天上午1粒吸入,治疗1年。在治疗前、治疗1月、3月、12后行肺功能检测;同期采用6 min步行距离评价运动能力,圣乔治呼吸问题调查问卷(SGRQ)评价生活质量。结果:在治疗3月及12月联合治疗组FEV1优于对照组(P均<0.01);在各治疗阶段联合治疗组6 min步行距离及SGRQ总评分均明显优于对照组(P<0.01)。结论:联合噻托溴铵治疗重度-极重度COPD能增加舒利迭对肺功能和生活质量的改善作用,早期改善COPD的运动耐量,延缓肺功能的下降。Objective To evaluate the clinical efficacy of salmeterol/fluticasone propionate（SFC） combined tiotropium bromide in patients with severe-to-very severe chronic obstructive pulmonary disease（COPD）.Methods A randomized,double-blind,controlled clinical trial was conducted in 47 stable severe-to-very severe patients with COPD.They were randomly given SFC（250μg/50μg） inhaling twice daily comined with tiotropium bromide（18 μg） or placebo inhaling once every am,which were defined as combined group and control group.The treatment was last for one year.The lung function was detected at 1 month,3months and 12months after administration,respectively.At the same time points,the movement function was evaluated with 6 minute walk distance（6-MWD） and the quality of life was assessed with St George＇s respiratory questionaire（SGRQ）.Results FEV1 in combined group was significantly superior to that of control group at the time of 3 months and 12 months（allP0.01）.6-MWD and SGRQ score in combined group were significantly superior to those of control group at all the time points（allP0.01）.Conclusion SFC combined with tiotropium bromide could further advance the efficacy of SFC in improving lung function and life quality,early improve the movement tolerance and delay the decrease of lung function in patients with COPD.

关 键 词：COPD 噻托溴铵 舒利迭 

分 类 号：R563.9[医药卫生—呼吸系统]